MetaVia Expands IP Portfolio to Enhance Treatment of Metabolic Diseases with Vanoglipel
- MetaVia has 48 patents to protect its lead candidate vanoglipel, targeting metabolic diseases like MASH and type 2 diabetes.
- Vanoglipel, a GPR119 agonist, shows promise in improving liver function and glucose management in clinical trials.
- The company is also developing DA-1726 to address obesity, emphasizing its commitment to innovative metabolic disease solutions.
MetaVia Strengthens Intellectual Property in Targeting Metabolic Diseases
MetaVia Inc., a clinical-stage biotechnology company based in Cambridge, Massachusetts, highlights its substantial progress with a comprehensive global intellectual property portfolio aimed at advancing its lead therapeutic candidate, vanoglipel (DA-1241). As a novel G-protein-coupled receptor 119 (GPR119) agonist, vanoglipel presents a promising avenue for treating cardiometabolic diseases, particularly Metabolic Dysfunction-Associated Steatohepatitis (MASH) and type 2 diabetes. The company currently boasts 48 granted and pending patents across key regions including the United States, Europe, Japan, and China, ensuring robust patent protection that may extend through 2035. This strong intellectual property foundation is crucial for MetaVia as it seeks to enhance the long-term market potential of vanoglipel.
The exclusive licensing of this patent portfolio from Dong-A ST Co., Ltd. underscores the strategic partnership that empowers MetaVia to protect its interests in the development of vanoglipel. CEO Hyung Heon Kim emphasizes that maintaining a solid intellectual property position is vital for maximizing the long-term value of the compound. Vanoglipel’s mechanism targets GPR119 in the gut, promoting the release of essential gut peptides that regulate metabolism. This approach not only aims to facilitate weight loss but also focuses on alleviating the underlying complications of serious metabolic conditions through well-supported scientific evidence.
Recent preclinical studies reveal vanoglipel’s efficacy in addressing hepatic steatosis, inflammation, and fibrosis, along with improvements in glucose management in various animal models of MASH and type 2 diabetes. Furthermore, data from Phase 1 and 2 clinical trials illustrate that vanoglipel is well-tolerated among both healthy individuals and those diagnosed with type 2 diabetes. The Phase 2a trials highlight the compound's capability to directly improve liver function while also providing glucose-lowering effects. This promising clinical profile not only strengthens MetaVia’s position in the biotechnology arena but also contributes to the broader mission of developing effective therapies for cardiometabolic disorders.
In addition to vanoglipel, MetaVia is in the process of developing another compound, DA-1726, to address obesity. This ongoing commitment to innovative solutions for metabolic diseases positions MetaVia as a significant player in the biotech landscape, aiming to provide holistic treatment options for serious health challenges.
Overall, MetaVia's advancing intellectual property posture and ongoing clinical developments reflect its strategic focus on unmet medical needs in cardiometabolic diseases, bolstering its role in addressing critical health concerns through targeted biotechnology initiatives.
